Treatment Science · Anagen
Topical T3 for the Scalp
The thyroid hormone your hair follicle already makes — delivered where it’s needed, not swallowed.
This is an early, honest dataset: a small uncontrolled observational study in people, plus ex-vivo human-scalp laboratory work. It is not a randomized controlled trial. We show the caveats next to the numbers.
The follicle runs a local thyroid system of its own.
The human hair follicle is not just a passive target for thyroid hormone arriving from the bloodstream. Organ-cultured human scalp follicles express thyroid-hormone receptors, and they transcribe the deiodinase enzymes (DIO2 and DIO3) that activate and inactivate thyroid hormone right inside the follicle. In other words, the follicle can tune its own T3 exposure independent of circulating levels.
What T3 does there, mechanistically:
- 1Prolongs anagen — the active growth phase — and supports hair-matrix biology.
- 2Drives intrafollicular mitochondrial biogenesis and ATP production — the energy supply anagen runs on.
- 3By analogy to liver and cell-line work, this likely reflects a generalizable THRB1 → PGC-1α → ERRα circuit that governs mitochondrial turnover — a mechanism not yet demonstrated in the hair follicle itself.
Deliver T3 to the follicle’s own thyroid machinery without flooding the body. An early in-vivo study found topical T3, delivered in liposomes, stimulated hair growth in mice and rats.
The picture is more interesting than “thyroid hormone grows hair.”
Working with Cutaneon and Prof. Ralf Paus (University of Miami), we treated organ-cultured human scalp skin from five donors with topical T3, T4, and their combination — across two candidate vehicles built from well-characterized, widely-used cosmetic / topical excipient ingredients — then read out fourteen hair-biology markers by quantitative immunohistomorphometry.
- 1Anagen, held longer (directional). T3 (10 nM) and T4 (10 µM) each trended toward prolonging anagen across three donors — not statistically significant (n = 20–35 follicles/3 donors), but the first time the signal has been reproduced after topical rather than culture-medium application.
- 2FGF-7/KGF, a hair-growth promoter, rose. Topical T3 and T4 increased FGF-7 in outer-root-sheath keratinocytes — significantly in one of the two vehicles (p < 0.001 for T3 1 nM; three donors) and as a non-significant trend in the other.
- 3The melanocyte system responded, tolerably. T3 tended toward stronger gp100 immunoreactivity and longer melanocyte dendrites, with no abnormal melanin clumping and no markers of follicle damage. Effects on melanin itself were vehicle- and dose-dependent and inconsistent, so we make no pigmentation claim — we read this as a tolerability signal, not an anti-greying one.
- 4A T3-favorable metabolic profile. T3 tended to lower phospho-S6 (mTORC1 activity) and mitochondrial MTCO1 — a pattern associated with follicle “rejuvenation” rather than over-drive — whereas T4 and the combination tended the other way.
- 5The case against T4 and the combination. T4 and the combination looked worse on several markers — lower hair-matrix proliferation, and (depending on the vehicle) higher TGFβ-2 or lower hair-shaft keratin K85 — arguments against topical T4 and against combining T3 with T4.
The ex-vivo case for T3 is a mechanism-and-safety case — favorable anagen, growth-factor, pigmentary and metabolic signals with a clean tolerability profile — which is why we took T3 (the 10 nM-class dose) into people, where the outcome that matters is measured directly. This dataset is published as a peer-reviewed pilot: Gherardini et al., Clinical & Experimental Dermatology, 2025.
Six patients, six months, tracked by trichoscopy.
Six patients used topical T3 and were tracked with trichoscopy (density and caliber) over six months. The signal here is density, not individual hair thickness.
With Patient 1 (who added microneedling) set aside, the mean falls to +18.6 follicles/cm² while the median (+14) is little changed. Caliber was flat-to-down across the cohort (mean −1.33 µm): the signal here is density, not individual hair thickness.
The honest read on this study — please weigh it:
- 1No placebo / control arm. This is observational, n = 6.
- 2Seasonality. The study ran February through August, heading into summer, when scalp hair density tends to rise and shedding tends to fall. Some of the gain may be seasonal rather than treatment-driven.
- 3Patient 1 added microneedling during the study. Microneedling grows hair on its own, so his standout +162 should not be read as a pure T3 effect; with him set aside, the mean falls to +18.6 follicles/cm² while the median (+14) is little changed.
- 4Three of six used other hair products — but each had been on them for more than six months before the study window (a stable baseline), with the exception of the microneedling noted above.
- 5Caliber was flat-to-down (mean −1.33 µm): the signal here is density, not individual hair thickness.
The Phase III trial of topical finasteride 0.25% reported a +20.2 hair increase in target-area hair count at 24 weeks, versus +6.7 for placebo — a placebo-subtracted gain of +13.5 hairs (Piraccini et al. 2022). Topical T3’s median (+21.5) and mean (+42.5 follicles/cm²) sit in a broadly similar range — but their trial is placebo-controlled while ours is uncontrolled, the two metrics differ (follicle density vs target-area hair count), and the mechanism is entirely different. They are not directly comparable.
Did it move systemic thyroid labs? An early n = 2 signal.
The central question for any topical thyroid hormone is simple: does it leak into the bloodstream and move your thyroid labs? In the subjects who checked, it didn’t move them meaningfully — small movements inside the normal interval, with no clinically meaningful systemic thyroid disruption.
| Subject | Free T3 (pg/mL) | Free T4 (ng/dL) | TSH (µIU/mL) | Read |
|---|---|---|---|---|
| Subject A | 3.7 → 4.2 | 1.31 → 1.23 | 1.02 → 1.80 | All within reference range |
| Subject B (~2 weeks) | 3.4 → 3.2 | 1.22 → 1.27 | 1.69 → 2.38 | All within range |
Small movements inside the normal interval, with no clinically meaningful systemic thyroid disruption. Two subjects, self-reported labs — directional reassurance, not a formal pharmacokinetic study.
Across the six-patient study, no serious adverse events.
Five of six reported nothing; one noted “slight redness when applied, nothing long-term.” This is consistent with the ex-vivo tolerability data, where topical T3 caused no pigmentary abnormalities and no markers of follicle damage.
T3 pairs naturally with TRH.
In follicular units treated with T3 + TRH across a dose range, RNA-seq showed a clear separation from baseline by principal- component analysis, with hundreds of differentially expressed genes at each dose (532 at the low dose) — enriching pathways that map onto hair growth.
Those pathways include HIF-1 signaling (suppressed in androgenetic alopecia; its stimulators grow hair) and a broad energy-metabolism reprogramming (glycolysis/gluconeogenesis, fatty-acid metabolism, PPAR, AMPK). The anagen follicle is glycolytic and energy-hungry; the combination appears to push that program toward growth.
Mechanistic transcriptomics, not a clinical endpoint. The RNA-seq describes which gene programs the combination moves — it does not measure hair regrowth in people.
A local thyroid axis
The follicle makes and tunes its own T3 (DIO2/DIO3); peer-reviewed ex-vivo work behind the rationale.
Published · ex vivo+21.5 median
Median +21.5 (mean +42.5) follicles/cm² over 6 months — small, uncontrolled, n = 6, with confounds.
Observed · n = 6Labs in range
Serum T3 / T4 / TSH stayed within range in the 2 subjects who tested; self-reported, not a PK study.
Self-reported · n = 20 of 6 serious AEs
One mild transient redness; consistent with ex-vivo tolerability (no damage, no pigmentary abnormalities).
Observed · n = 6What remains unproven
- No randomized controlled trial. The human data is a small, uncontrolled, n = 6 observational study, with the seasonality, microneedling and concurrent-treatment confounds spelled out in §03.
- Density, not caliber. Mean shaft thickness was flat-to-slightly-negative.
- Ex-vivo T3-alone did not increase hair-shaft elongation. The ex-vivo case for T3 is mechanistic and tolerability-based, not direct growth.
- No formal human pharmacokinetic / skin-permeation study quantifying how much T3 reaches the follicle versus the circulation; the serum reassurance comes from two subjects.
- Narrow therapeutic index. T3 (liothyronine) has a narrow therapeutic index systemically, with cardiac considerations; the local-only thesis is supported here but not formally proven across users.
